+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gene Therapy for Sickle Cell Disease Market - Global Forecast 2026-2032- Product Image
Gene Therapy for Sickle Cell Disease Market - Global Forecast 2026-2032- Product Image
Sale

Gene Therapy for Sickle Cell Disease Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118326
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gene Therapy for Sickle Cell Disease Market is projected to reach USD 2.49 Billion in 2026. It is expected to continue growing at a CAGR of 13.60%, reaching USD 5.25 Billion by 2032.

Gene Therapy for Sickle Cell Disease: Executive Overview

Gene therapy is changing the treatment discussion for sickle cell disease by targeting the biological causes of severe disease rather than relying solely on repeated supportive care. The approach includes genetic modification of a patient’s own hematopoietic stem cells and, in some cases, editing regulatory pathways that influence fetal hemoglobin production. Clinical and regulatory progress has established gene therapy as a potentially durable option for selected patients, while access, conditioning toxicity, specialist capacity, long-term monitoring, and affordability remain central considerations.

From Chronic Management Toward Potentially Durable Treatment

The landscape is shifting from episodic management of vaso-occlusive crises and chronic complications toward treatment strategies intended to produce sustained increases in functional hemoglobin and reduce disease manifestations. This transition requires more than therapeutic efficacy: hospitals need cell-collection, manufacturing coordination, transplantation, intensive-care, and follow-up capabilities. Patient selection is also becoming more structured, with attention to disease severity, organ health, fertility considerations, treatment readiness, and the risks associated with myeloablative conditioning.

Artificial Intelligence Strengthens Design, Selection, and Monitoring

Artificial intelligence can support gene-therapy development by improving target discovery, analyzing genomic and transcriptomic data, and identifying patterns associated with treatment response or adverse events. In clinical practice, machine-learning tools may help prioritize eligible patients, interpret laboratory trends, coordinate complex treatment pathways, and detect complications earlier. These applications require rigorous validation, explainability, privacy safeguards, and representative datasets, particularly because sickle cell disease populations are geographically diverse and historically underserved by biomedical data systems.

Regional Differences Reflect Infrastructure, Regulation, and Health Equity

North America has comparatively developed advanced-therapy infrastructure, but treatment availability remains concentrated in specialized centers and is shaped by reimbursement and referral capacity. Europe combines sophisticated clinical networks with differing national assessment and funding processes. Asia-Pacific includes strong capabilities in Australia, Japan, South Korea, and selected urban centers, alongside major access variation across the region. Latin America faces uneven diagnostic coverage, specialist availability, and public financing. The Middle East is expanding tertiary-care and genomic-medicine capacity, while the African region carries a substantial disease burden but often faces limited screening, transplantation infrastructure, and access to advanced therapies. Across all regions, newborn screening, genetic counseling, registry development, and long-term follow-up are essential complements to treatment innovation.

Economic and Diplomatic Groups Shape Access Pathways

ASEAN countries face wide variation in screening systems, specialist capacity, regulatory maturity, and cross-border referral options. BRICS members combine significant scientific and manufacturing capabilities with substantial differences in public-health resources and treatment access. The European Union benefits from shared scientific and regulatory coordination, although national reimbursement and delivery arrangements remain distinct. G7 members generally possess advanced research and clinical infrastructure, yet affordability and equitable referral remain important challenges. GCC states are investing in specialized healthcare and genomic services, while workforce development and regional coordination remain relevant. NATO countries span diverse health systems, making interoperability, emergency preparedness, and equitable access to specialist care important policy considerations.

Country-Level Priorities Across Established and Emerging Systems

Australia has strong specialist-care capacity but must address geographic access and Indigenous health inequities. Brazil faces a large public-health burden and needs consistent specialist referral, financing, and follow-up. Canada’s dispersed population makes coordinated referral and regional treatment access important. China is expanding advanced biomedical capabilities while regulatory, reimbursement, and regional-access considerations remain significant. France, Germany, Italy, Spain, and the United Kingdom have established hematology networks, but national assessment, funding, and center-capacity requirements differ. India requires broader diagnosis, specialist infrastructure, and affordability solutions across public and private systems. Japan and South Korea have advanced clinical and regulatory capabilities, with attention to eligibility, long-term surveillance, and equitable access. Mexico continues to need stronger detection, specialist capacity, and sustainable financing. Russia’s access is influenced by regional disparities, specialized infrastructure, and regulatory conditions. The United States has substantial clinical and research capacity, while insurance coverage, center availability, and disparities in diagnosis and referral remain material issues.

Build the Delivery Ecosystem Before Expanding Patient Access

Industry leaders should prioritize evidence generation that reflects real-world disease diversity and includes long-term safety, durability, fertility, quality-of-life, and organ-outcome measures. They should develop partnerships with treatment centers to strengthen collection, conditioning, cell handling, genomic testing, and follow-up capabilities; create transparent patient-selection and informed-consent processes; and support registries that enable consistent post-treatment monitoring. Access strategies should address payer evidence needs, travel and lodging burdens, workforce shortages, and referral delays. Responsible use of artificial intelligence should include clinical validation, bias testing, cybersecurity, human oversight, and clear accountability. Engagement with patients, caregivers, clinicians, regulators, and public-health authorities can improve trust and ensure that innovation is aligned with practical care needs.

Research Methodology for a Reliable Executive Assessment

This executive summary uses the supplied market definition-gene therapy for sickle cell disease-and synthesizes verified, non-estimative evidence from established categories of sources, including peer-reviewed clinical research, regulatory communications, treatment guidelines, public-health surveillance, health-technology assessments, and published health-system data. Findings are organized by technology, care delivery, artificial intelligence, region, economic grouping, and country. The assessment emphasizes documented clinical, regulatory, infrastructure, and access conditions. It excludes market estimates, market shares, forecasts, and unsupported company-specific claims, and recognizes that country-level implementation can change as evidence, regulation, reimbursement, and clinical capacity evolve.

Durable Potential Depends on Equitable, Long-Term Implementation

Gene therapy offers a meaningful shift in the therapeutic possibilities for people with severe sickle cell disease, but its value will depend on safe delivery, durable follow-up, and equitable access rather than scientific progress alone. Regional infrastructure, national financing, specialist capacity, patient trust, and long-term evidence will determine how broadly these therapies improve outcomes. Leaders that combine rigorous clinical stewardship with coordinated health-system investment and responsible data use will be best positioned to translate gene-therapy advances into sustainable patient benefit.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gene Therapy for Sickle Cell Disease Market, by Treatment Model
7.1. Introduction
7.2. Allogeneic
7.3. Autologous
8. Gene Therapy for Sickle Cell Disease Market, by Modification Technology
8.1. Introduction
8.2. Base Editing
8.3. Cripr/Cas9
8.4. Lentiviral Vector
8.5. Zinc Finger Nuclease
9. Gene Therapy for Sickle Cell Disease Market, by Severity
9.1. Introduction
9.2. Moderate
9.3. Severe
10. Gene Therapy for Sickle Cell Disease Market, by Payer Category
10.1. Introduction
10.2. Government
10.3. Out Of Pocket
10.4. Private
11. Gene Therapy for Sickle Cell Disease Market, by Patient Age
11.1. Introduction
11.2. Adult
11.3. Pediatric
12. Gene Therapy for Sickle Cell Disease Market, by Distribution Channel
12.1. Introduction
12.2. Hospital
12.3. Specialty Treatment Center
13. Gene Therapy for Sickle Cell Disease Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Gene Therapy for Sickle Cell Disease Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Gene Therapy for Sickle Cell Disease Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Agios Pharmaceuticals, Inc.
17.2. Beam Therapeutics, Inc.
17.3. Bluebird Bio, Inc.
17.4. Bristol-Myers Squibb Company
17.5. CRISPR Therapeutics AG
17.6. Editas Medicine, Inc.
17.7. EditForce, Inc.
17.8. Emmaus Life Sciences, Inc.
17.9. F. Hoffmann-La Roche Ltd.
17.10. Fulcrum Therapeutics, Inc.
17.11. Global Blood Therapeutics, Inc.
17.12. Graphite Bio, Inc.
17.13. Homology Medicines, Inc.
17.14. Imara, Inc.
17.15. Incyte Corporation
17.16. Intellia Therapeutics, Inc.
17.17. JCR Pharmaceuticals Co., Ltd.
17.18. Magenta Therapeutics, Inc.
17.19. Novartis AG
17.20. Pfizer Inc.
17.21. Precision BioSciences, Inc.
17.22. Sangamo Therapeutics, Inc.
17.23. Sanofi S.A.
17.24. Vertex Pharmaceuticals Incorporated
17.25. Vifor Pharma AG
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Gene Therapy for Sickle Cell Disease Market, Years Considered for the Study
FIGURE 2. Global Gene Therapy for Sickle Cell Disease Market, Research Design
FIGURE 3. Global Gene Therapy for Sickle Cell Disease Market, Research Framework
FIGURE 4. Global Gene Therapy for Sickle Cell Disease Market, Data Triangulation
FIGURE 5. Global Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2025 vs 2032 (%)
FIGURE 7. Global Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2025 vs 2032 (%)
FIGURE 9. Global Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2025 vs 2032 (%)
FIGURE 11. Global Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2025 vs 2032 (%)
FIGURE 13. Global Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2025 vs 2032 (%)
FIGURE 15. Global Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Gene Therapy for Sickle Cell Disease Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Gene Therapy for Sickle Cell Disease Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Gene Therapy for Sickle Cell Disease Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Gene Therapy for Sickle Cell Disease Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Gene Therapy for Sickle Cell Disease Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Gene Therapy for Sickle Cell Disease Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Gene Therapy for Sickle Cell Disease Market Segmentation & Coverage
TABLE 2. Global Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 4. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 11. Global Base Editing Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Base Editing Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Base Editing Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Cripr/Cas9 Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Cripr/Cas9 Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Cripr/Cas9 Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Lentiviral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Lentiviral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Lentiviral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Zinc Finger Nuclease Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Zinc Finger Nuclease Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Zinc Finger Nuclease Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 24. Global Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 31. Global Government Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Government Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Government Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Out Of Pocket Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Out Of Pocket Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Out Of Pocket Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Private Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Private Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Private Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 41. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 48. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Specialty Treatment Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Specialty Treatment Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Specialty Treatment Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Gene Therapy for Sickle Cell Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. North America Gene Therapy for Sickle Cell Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. North America Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 64. North America Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 65. North America Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 66. North America Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 67. North America Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 68. North America Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 69. Latin America Gene Therapy for Sickle Cell Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Latin America Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 71. Latin America Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 72. Latin America Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 73. Latin America Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 74. Latin America Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 75. Latin America Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. Europe Gene Therapy for Sickle Cell Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Europe Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 78. Europe Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 79. Europe Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 80. Europe Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 81. Europe Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 82. Europe Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Middle East Gene Therapy for Sickle Cell Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Middle East Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 85. Middle East Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 86. Middle East Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 87. Middle East Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 88. Middle East Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 89. Middle East Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. Africa Gene Therapy for Sickle Cell Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Africa Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 92. Africa Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 93. Africa Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 94. Africa Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 95. Africa Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 96. Africa Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. Global Gene Therapy for Sickle Cell Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. ASEAN Gene Therapy for Sickle Cell Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. ASEAN Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 100. ASEAN Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 101. ASEAN Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 102. ASEAN Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 103. ASEAN Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 104. ASEAN Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. GCC Gene Therapy for Sickle Cell Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. GCC Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 107. GCC Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 108. GCC Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 109. GCC Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 110. GCC Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 111. GCC Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. European Union Gene Therapy for Sickle Cell Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. European Union Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 114. European Union Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 115. European Union Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 116. European Union Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 117. European Union Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 118. European Union Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. BRICS Gene Therapy for Sickle Cell Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. BRICS Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 121. BRICS Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 122. BRICS Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 123. BRICS Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 124. BRICS Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 125. BRICS Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. G7 Gene Therapy for Sickle Cell Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. G7 Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 128. G7 Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 129. G7 Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 130. G7 Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 131. G7 Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 132. G7 Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. NATO Gene Therapy for Sickle Cell Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. NATO Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 135. NATO Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 136. NATO Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 137. NATO Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 138. NATO Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 139. NATO Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Global Gene Therapy for Sickle Cell Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 141. United States Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 142. United States Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 143. United States Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 144. United States Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 145. United States Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 146. United States Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 147. United States Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. Canada Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 149. Canada Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 150. Canada Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 151. Canada Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 152. Canada Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 153. Canada Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 154. Canada Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. Mexico Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 156. Mexico Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 157. Mexico Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 158. Mexico Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 159. Mexico Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 160. Mexico Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 161. Mexico Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Brazil Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 163. Brazil Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 164. Brazil Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 165. Brazil Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 166. Brazil Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 167. Brazil Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 168. Brazil Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. United Kingdom Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 170. United Kingdom Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 171. United Kingdom Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 172. United Kingdom Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 173. United Kingdom Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 174. United Kingdom Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 175. United Kingdom Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Germany Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 177. Germany Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 178. Germany Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 179. Germany Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 180. Germany Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 181. Germany Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 182. Germany Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. France Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 184. France Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 185. France Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 186. France Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 187. France Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 188. France Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 189. France Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Russia Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 191. Russia Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 192. Russia Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 193. Russia Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 194. Russia Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 195. Russia Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 196. Russia Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. Italy Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 198. Italy Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 199. Italy Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 200. Italy Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 201. Italy Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 202. Italy Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 203. Italy Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Spain Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 205. Spain Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 206. Spain Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 207. Spain Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 208. Spain Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 209. Spain Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 210. Spain Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 211. China Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 212. China Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 213. China Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 214. China Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 215. China Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 216. China Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 217. China Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. India Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 219. India Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 220. India Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 221. India Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 222. India Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 223. India Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 224. India Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. Japan Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 226. Japan Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 227. Japan Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 228. Japan Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 229. Japan Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 230. Japan Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 231. Japan Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. Australia Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 233. Australia Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 234. Australia Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 235. Australia Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 236. Australia Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 237. Australia Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 238. Australia Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. South Korea Gene Therapy for Sickle Cell Disease Market Size, 2017-2032 (USD Million)
TABLE 240. South Korea Gene Therapy for Sickle Cell Disease Market Size, by Treatment Model, 2017-2032 (USD Million)
TABLE 241. South Korea Gene Therapy for Sickle Cell Disease Market Size, by Modification Technology, 2017-2032 (USD Million)
TABLE 242. South Korea Gene Therapy for Sickle Cell Disease Market Size, by Severity, 2017-2032 (USD Million)
TABLE 243. South Korea Gene Therapy for Sickle Cell Disease Market Size, by Payer Category, 2017-2032 (USD Million)
TABLE 244. South Korea Gene Therapy for Sickle Cell Disease Market Size, by Patient Age, 2017-2032 (USD Million)
TABLE 245. South Korea Gene Therapy for Sickle Cell Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. Global Gene Therapy for Sickle Cell Disease Market Share, by Key Player, 2025
TABLE 247. Global Gene Therapy for Sickle Cell Disease Market, Key Experts

Companies Mentioned

  • Agios Pharmaceuticals, Inc.
  • Beam Therapeutics, Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • EditForce, Inc.
  • Emmaus Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulcrum Therapeutics, Inc.
  • Global Blood Therapeutics, Inc.
  • Graphite Bio, Inc.
  • Homology Medicines, Inc.
  • Imara, Inc.
  • Incyte Corporation
  • Intellia Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Magenta Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Vertex Pharmaceuticals Incorporated
  • Vifor Pharma AG

Related Topics

Related Reports

Gene Therapy Market - Global Forecast 2026-2032 - Product Image

Gene Therapy Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2026-2034 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2026-2034

  • Report
  • 140 Pages
  • Global
From
Carrier Screening - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Carrier Screening - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Global Report 2026 - Product Image

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Global Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.